CN Patent

CN102834105A — 保护免受机械通气诱导的膈膜功能障碍和骨骼肌萎缩的线粒体靶向的抗氧化剂

Assigned to Cornell University · Expires 2012-12-19 · 13y expired

What this patent protects

本发明提供用于预防或治疗哺乳动物对象中的MV-诱导的或废用-诱导的骨骼肌衰弱的方法和组合物。所述方法还包括将有效量的芳香族阳离子肽给药至所述对象。

USPTO Abstract

本发明提供用于预防或治疗哺乳动物对象中的MV-诱导的或废用-诱导的骨骼肌衰弱的方法和组合物。所述方法还包括将有效量的芳香族阳离子肽给药至所述对象。

Drugs covered by this patent

elamipretide-hydrochloride (ELAMIPRETIDE HYDROCHLORIDE)

Patent Metadata

Patent number: CN102834105A
Jurisdiction: CN
Classification: —
Expires: 2012-12-19
Drug substance claim: No
Drug product claim: No
Assignee: Cornell University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.